The Medicines and Healthcare products Regulatory Agency has opened a public consultation on the proposal to restrict access to the availability of pseudoephedrine and ephedrine.
This consultation is in response to the Annual Report of the International Narcotics Control Board that identified that these medicines are used in the illegal manufacture of methylamphetamine, a Class A drug more commonly known as crystal meth.
Action: All healthcare professionals should be aware of the consultation and of the potential to illegally use pseudoephedrine and ephedrine in the manufacture of a Class A drug. Supplies of both drugs should be restricted to ensure inappropriate use is kept to a minimum.
|« Bone quality discussed in PLoS Medicine||SMC latest advice »|